Fox Run Management L.L.C. Acquires Shares of 16,667 Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Fox Run Management L.L.C. bought a new position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The fund bought 16,667 shares of the biopharmaceutical company's stock, valued at approximately $1,392,000.

Other hedge funds have also recently made changes to their positions in the company. Atria Investments Inc increased its stake in Intra-Cellular Therapies by 41.1% during the third quarter. Atria Investments Inc now owns 5,137 shares of the biopharmaceutical company's stock worth $376,000 after acquiring an additional 1,497 shares during the last quarter. CIBC Asset Management Inc bought a new position in shares of Intra-Cellular Therapies during the 3rd quarter valued at approximately $205,000. Swiss National Bank increased its position in shares of Intra-Cellular Therapies by 8.1% during the 3rd quarter. Swiss National Bank now owns 185,500 shares of the biopharmaceutical company's stock valued at $13,573,000 after purchasing an additional 13,900 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG purchased a new stake in Intra-Cellular Therapies during the 3rd quarter valued at $2,436,000. Finally, Avior Wealth Management LLC lifted its holdings in shares of Intra-Cellular Therapies by 3.0% in the 3rd quarter. Avior Wealth Management LLC now owns 4,473 shares of the biopharmaceutical company's stock worth $327,000 after acquiring an additional 131 shares during the last quarter. 92.33% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on ITCI shares. Piper Sandler reiterated a "neutral" rating and set a $132.00 price target (up from $107.00) on shares of Intra-Cellular Therapies in a report on Tuesday, January 14th. Canaccord Genuity Group cut Intra-Cellular Therapies from a "buy" rating to a "hold" rating and upped their target price for the company from $119.00 to $132.00 in a research note on Friday, January 31st. Leerink Partnrs cut Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a report on Monday, January 13th. Royal Bank of Canada reissued a "sector perform" rating and set a $132.00 target price (up from $108.00) on shares of Intra-Cellular Therapies in a research note on Wednesday, January 22nd. Finally, Cantor Fitzgerald raised shares of Intra-Cellular Therapies from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, January 14th. Ten analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $106.08.

Remove Ads

Intra-Cellular Therapies Stock Performance

Shares of Intra-Cellular Therapies stock traded up $0.05 during trading on Tuesday, hitting $131.75. 504,255 shares of the company's stock were exchanged, compared to its average volume of 1,336,142. The stock has a market capitalization of $14.01 billion, a price-to-earnings ratio of -151.44 and a beta of 0.69. The business has a 50-day simple moving average of $128.70 and a 200-day simple moving average of $98.18. Intra-Cellular Therapies, Inc. has a 52-week low of $64.09 and a 52-week high of $131.71.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last issued its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.08). The company had revenue of $199.22 million during the quarter, compared to analyst estimates of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. On average, equities analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current fiscal year.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.